[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/ microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of solid tumors; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. The company was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 89, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 36, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thorsten  Graef M.D., Ph.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 60, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.54, "open": 2.42, "dayLow": 2.29, "dayHigh": 2.53, "regularMarketPreviousClose": 2.54, "regularMarketOpen": 2.42, "regularMarketDayLow": 2.29, "regularMarketDayHigh": 2.53, "payoutRatio": 0.0, "forwardPE": -0.70724636, "volume": 77919, "regularMarketVolume": 77919, "averageVolume": 98250, "averageVolume10days": 89220, "averageDailyVolume10Day": 89220, "bid": 2.37, "ask": 2.48, "bidSize": 1, "askSize": 1, "marketCap": 59445964, "fiftyTwoWeekLow": 2.29, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": 236.83652, "fiftyDayAverage": 4.3682, "twoHundredDayAverage": 9.466508, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -111627992, "profitMargins": 0.0, "floatShares": 4396812, "sharesOutstanding": 24363100, "sharesShort": 854100, "sharesShortPriorMonth": 1183120, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0352, "heldPercentInsiders": 0.22633, "heldPercentInstitutions": 0.90846, "shortRatio": 9.98, "shortPercentOfFloat": 0.0354, "impliedSharesOutstanding": 25662500, "bookValue": 7.683, "priceToBook": 0.31758428, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -65373000, "trailingEps": -5.81, "forwardEps": -3.45, "enterpriseToRevenue": -444.733, "enterpriseToEbitda": 1.721, "52WeekChange": -0.7966667, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 2.44, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 20.4, "targetMedianPrice": 20.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 185428000, "totalCashPerShare": 7.611, "ebitda": -64851000, "totalDebt": 14354000, "quickRatio": 15.219, "currentRatio": 15.395, "totalRevenue": 251000, "debtToEquity": 7.691, "revenuePerShare": 0.022, "returnOnAssets": -0.26725, "returnOnEquity": -0.54243, "grossProfits": 251000, "freeCashflow": -33753248, "operatingCashflow": -55032000, "revenueGrowth": -1.0, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -268.0558, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "marketState": "CLOSED", "priceEpsCurrentYear": -0.96062994, "fiftyDayAverageChange": -1.9281998, "fiftyDayAverageChangePercent": -0.4414175, "twoHundredDayAverageChange": -7.026508, "twoHundredDayAverageChangePercent": -0.7422492, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "postMarketChangePercent": 6.55737, "postMarketPrice": 2.6, "postMarketChange": 0.16, "regularMarketChange": -0.099999905, "regularMarketDayRange": "2.29 - 2.53", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 98250, "firstTradeDateMilliseconds": 1721395800000, "fiftyTwoWeekLowChange": 0.1500001, "fiftyTwoWeekLowChangePercent": 0.06550223, "fiftyTwoWeekRange": "2.29 - 17.31", "fiftyTwoWeekHighChange": -14.869999, "fiftyTwoWeekHighChangePercent": -0.859041, "fiftyTwoWeekChangePercent": -79.66667, "epsTrailingTwelveMonths": -5.81, "epsForward": -3.45, "epsCurrentYear": -2.54, "regularMarketChangePercent": -3.937004, "regularMarketPrice": 2.44, "corporateActions": [], "postMarketTime": 1743799557, "regularMarketTime": 1743796803, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]